Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects-Reference-Cited by-同舟云学术

Tolerability and Pharmacokinetics of Lobeglitazone (CKD-501), a Peroxisome Proliferator-Activated Receptor-γ Agonist: A Single- and Multiple-Dose, Double-Blind, Randomized Control Study in Healthy Male Korean Subjects

Published:2011-11 Issue:11 Volume:33 Page:1819-1830
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Kim Jung Won,Kim Jung-Ryul,Yi SoJeong,Shin Kwang-Hee,Shin Hyun-Suk,Yoon Seo Hyun,Cho Joo-Youn,Kim Dal-Hyun,Shin Sang-Goo,Jang In-Jin,Yu Kyung-Sang

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes;Henry;Clin Ther,2003

2. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta;Evans;Curr Diabetes Rev,2005

3. Controlling the ABCs of diabetes in clinical practice: a community-based endocrinology practice experience;Varma;Diabetes Res Clin Pr,2008

4. PPAR dual agonists: are they opening Pandora's Box?;Balakumar;Pharmacol Res,2007

5. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study;Jurado;J Am Acad Nurse Prac,2009

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lobeglitazone and Its Therapeutic Benefits: A Review;Cureus;2023-12-06

2. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study;Cardiovascular Diabetology;2023-05-05

3. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-04

4. Evaluation of pharmacokinetic interactions between lobeglitazone, empagliflozin, and metformin in healthy subjects;Translational and Clinical Pharmacology;2023

5. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus;Diabetes & Metabolism Journal;2022-11-30